NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy
Stocks in this Quantisnow insightHealth Care
Historical context for NCEL
Across the 5 sessions after earlier NCEL headlines, the stock closed higher 3 times and lower 2 times, with a median move of 10.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | NCEL | SPY |
|---|---|---|---|
| Jan 29, 2026 | NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences | -3.4% | -0.2% |
| Jan 12, 2026 | NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression | +13.7% | +0.2% |
| Jan 5, 2026 | NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board | +6.7% | +0.7% |
| Dec 11, 2025 | NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China | -21.8% | +0.2% |
| Nov 4, 2025 | NewcelX CEO Issues Letter to Shareholders | +10.0% | -1.2% |
Quantisnow market dataNASDAQ
NCEL
NewcelX Ltd.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Get push alerts for NCEL
Full NCEL profile on Quantisnow Follow NCEL and get a push notification the moment its next story breaks.